News Posts List
Prescription Drug Reimportation and the Economic Downturn
05/05/2009
Wyeth v. Levine caused undeserved loss to Wyeth that will increase uncertainty in product labeling and hence increase litigation and losses for the entire industry, and will probably undermine future research too.
Full Kidney Removal Not Necessary for All Kidney Tumors
05/05/2009
Early-stage renal masses should be treated with nephron-sparing approaches when possible.
How to Fix Medicare
05/04/2009
Should Medicare pay for patient expenses the way automobile insurers pay for car-repair bills?
Star of E! Reality Series "It's Complicated" Raises Funds For Kidney Cancer
05/03/2009
We lost my mom, Joni, a little over a year ago to kidney cancer and the Kidney Cancer Association is based in Chicago. I wanted to do something in honor of my mom and help them raise awareness.
Treatment blow to Rugby kidney cancer patient
05/02/2009
KIDNEY cancer patients and leading specialists have slammed a proposal to stop providing three life-lengthening treatments on the NHS.
Actress Denise Richards Raises Funds For Kidney Cancer Research
05/02/2009
Richards was at the event supporting the Kidney Cancer Association, a cause close to her heart after she lost her mother to the disease a year ago.
Health care should not be brokered by US politicians
05/01/2009
Editorial: Should we let Washington bureaucrats decide when to pull the plug on us?
New Aussie subsidy for kidney cancer drug
05/01/2009
Lagging the USA by years, hundreds of Australian patients being treated for renal cell carcinoma - a major form of kidney cancer - will benefit from Government-subsidised access to sunitinib.
NICE says NO to kidney cancer drugs on the NHS
04/30/2009
The National Institute for Health and Clinical Excellence has denied patients with kidney cancer access to Roches Avastin (bevacizumab), Bayers Nexavar (sorafenib) and Wyeths Torisel (temsirolimus) on the National Health Service.
FDA grants orphan drug status to Oncophage
04/30/2009
The FDA granted orphan drug status to Oncophage as a brain cancer treatment, allowing up to 7 years of market exclusivity if approved for the indication.
News Feed